Literature DB >> 8373270

Are positive axillary nodes in breast cancer markers for incurable disease?

B Gardner1, J Feldman.   

Abstract

OBJECTIVE: This study was designed to determine if resection of positive regional nodes in patients with breast cancer provided a group of cured patients. SUMMARY BACKGROUND DATA: Previous studies of long-term follow-up of patients with breast cancer have demonstrated that 30% of patients with positive nodes may be alive at 10 or 20 years. Randomized, prospective studies have not shown a difference in survival between modified radical and total mastectomy.
METHODS: The authors analyzed the statistical basis of randomized, prospective studies of breast cancer. Patients from University and Kings County Hospital with breast cancer were observed (n = 1024) and the 10-year survival curves were analyzed. Data from the Surveillance, Epidemiology, and End Results (SEER) program were evaluated to determine the prognosis of patients with positive-node breast cancer who survived 10 and 15 years.
RESULTS: The authors found that no current randomized study of primary treatment of breast cancer has the power to determine the advantage of one treatment over another if the primary cancer is treated. Additionally, evaluation of the patients in this study demonstrated that those with regional disease usually had a recurrence by 7 years; however, at 10 years, 30% are still alive and have the same prognosis as patients with negative-node breast cancer.
CONCLUSIONS: Regional breast cancer is a curable disease in some resected patients.

Entities:  

Mesh:

Year:  1993        PMID: 8373270      PMCID: PMC1242961          DOI: 10.1097/00000658-199309000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  10 in total

1.  Carcinoma of the breast.

Authors:  R S Handley
Journal:  Ann R Coll Surg Engl       Date:  1975-08       Impact factor: 1.891

2.  Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy.

Authors:  H J BLOOM; W W RICHARDSON; E J HARRIES
Journal:  Br Med J       Date:  1962-07-28

3.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

4.  Long-term followup of breast cancer patients: the 30-year report.

Authors:  F Adair; J Berg; L Joubert; G F Robbins
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

5.  Number of lymph nodes examined and the prognosis of breast carcinoma.

Authors:  B Fisher; N H Slack
Journal:  Surg Gynecol Obstet       Date:  1970-07

6.  Significance of axillary macrometastases and micrometastases in mammary cancer.

Authors:  A G Huvos; R V Hutter; J W Berg
Journal:  Ann Surg       Date:  1971-01       Impact factor: 12.969

7.  Analysis of survival and recurrence vs. patient and doctor delay in treatment of breast cancer.

Authors:  C R Dennis; B Gardner; B Lim
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

8.  Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size.

Authors:  P P Rosen; P E Saigo; D W Braun; E Weathers; A A Fracchia; D W Kinne
Journal:  Ann Surg       Date:  1981-11       Impact factor: 12.969

9.  Discontinuous or "skip" metastases in breast carcinoma. Analysis of 1228 axillary dissections.

Authors:  P P Rosen; M L Lesser; D W Kinne; E J Beattie
Journal:  Ann Surg       Date:  1983-03       Impact factor: 12.969

10.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

  10 in total
  4 in total

1.  Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications.

Authors:  S L Kong; M Salto-Tellez; A P K Leong; Y H Chan; E S C Koay
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

2.  Previstage GCC test for staging patients with colorectal cancer.

Authors:  Alex Mejia; Scott A Waldmana
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

3.  Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study.

Authors:  William E Gillanders; Kaidi Mikhitarian; Renee Hebert; Patrick D Mauldin; Yuko Palesch; Christian Walters; Marshall M Urist; G Bruce Mann; Gerard Doherty; Virginia M Herrmann; Arnold D Hill; Oleg Eremin; Mohamed El-Sheemy; Richard K Orr; Alvaro A Valle; Michael A Henderson; Robert L Dewitty; Sonia L Sugg; Eric Frykberg; Karen Yeh; Richard M Bell; John S Metcalf; Bruce M Elliott; Thomas Brothers; Jay Robison; Michael Mitas; David J Cole
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

4.  A rapid nested polymerase chain reaction method to detect circulating cancer cells in breast cancer patients using multiple marker genes.

Authors:  Lei Liu; Chunhu Ma; Qian Xu; Luyang Cheng; Lijun Xiao; Dawei Xu; Yaxian Gao; Jianping Wang; Hongru Song
Journal:  Oncol Lett       Date:  2014-04-08       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.